Sarepta Therapeutics plummets 20% after FDA contradicts company and requires advisory meeting

Sarepta Therapeutics Inc.

shares plummeted in the extended session Thursday after the Food and Drug Administration contradicted the biotech company and said it required an advisory committee meeting for its experimental Duchenne muscular dystrophy drug. Shares of Sarepta dropped as much as 20% after hours, following a 2.9% gain in the regular session to close at $149.67. At the beginning of the month, Sarepta said the FDA did not plan on requiring a meeting, and shares soared 23.5% that day.

shares plummeted in the extended session Thursday after the Food and Drug Administration contradicted the biotech company and said it required an advisory committee meeting for its experimental Duchenne muscular dystrophy drug. Shares of Sarepta dropped as much as 20% after hours, following a 2.9% gain in the regular session to close at $149.67. At the beginning of the month, Sarepta said the FDA did not plan on requiring a meeting, and shares soared 23.5% that day.

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

MarketWatch /  🏆 3. in CH

Sounds like the FDA knows more about Sarepta than they do.

Switzerland Neuesten Nachrichten, Switzerland Schlagzeilen